Integral Diagnostics Ltd

IDX: XASX (AUS)
View Stock Summary
Morningstar Rating for StocksFair ValueEconomic MoatCapital Allocation
LOCK|&q?#@$LOCK|?VLOCK|h$cW$pY

Integral Diagnostics: Trading Update Broadly in Line With Our Expectations

No-moat Integral Diagnostic’s first-quarter fiscal 2025 group revenue grew 8.6% on the previous corresponding period. Australian revenue growth was slightly below market and our expectations. However, New Zealand's revenue growth was strong, and we leave our full-year organic group revenue growth forecast of 8.6% unchanged, albeit slightly different compositionally. Given a delay in regulatory approval, we now credit six months earnings contributions from Capitol Health in fiscal 2025 versus nine months previously. We maintain our AUD 3.40 fair value estimate, with shares appearing slightly undervalued.

Sponsor Center